Timothy Hoey Ph.D.
Net Worth
Last updated:
What is Timothy Hoey Ph.D. net worth?
The estimated net worth of Dr. Timothy Hoey Ph.D. is at least $1,848,232 as of 5 Mar 2024. He owns shares worth $282,148 as insider, has earned $145,404 from insider trading and has received compensation worth at least $1,420,680 in Tenaya Therapeutics, Inc..
What is the salary of Timothy Hoey Ph.D.?
Dr. Timothy Hoey Ph.D. salary is $473,560 per year as Chief Scientific Officer in Tenaya Therapeutics, Inc..
How old is Timothy Hoey Ph.D.?
Dr. Timothy Hoey Ph.D. is 66 years old, born in 1959.
What stocks does Timothy Hoey Ph.D. currently own?
As insider, Dr. Timothy Hoey Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Tenaya Therapeutics, Inc. (TNYA) | Chief Scientific Officer | 245,346 | $1.15 | $282,148 |
What does Tenaya Therapeutics, Inc. do?
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Timothy Hoey Ph.D. insider trading
Tenaya Therapeutics, Inc.
Dr. Timothy Hoey Ph.D. has made 7 insider trades between 2022-2024, according to the Form 4 filled with the SEC. Most recently he sold 3,300 units of TNYA stock worth $23,100 on 5 Mar 2024.
The largest trade he's ever made was exercising 7,243 units of TNYA stock on 29 Aug 2023. As of 5 Mar 2024 he still owns at least 245,346 units of TNYA stock.
Tenaya Therapeutics key executives
Tenaya Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Deepak Srivastava M.D. (59) Scientific Founder, Chairman of Scientific Advisory Board & Director
- Dr. Timothy Hoey Ph.D. (66) Chief Scientific Officer
- Mr. Faraz Ali M.B.A. (52) Chief Executive Officer, Sec. & Director
- Mr. Whittemore G. Tingley M.D., PH.D. (58) Chief Medical Officer